Key Takeaways
- Pharmaceutical outsourcing frees up capacity and significantly reduces capital expenditure
- Contract filling is particularly beneficial in the event of capacity bottlenecks, new product lines and a lack of GMP infrastructure
- Choosing the right CMO depends on quality standards, flexibility and regulatory expertise
- Outsourcing is not a stopgap measure, but a strategic decision with measurable benefits
- As a specialist CMO, Lubecafill offers flexible filling solutions for sterile and pharmaceutical products
What is pharmaceutical outsourcing?
For many companies, pharmaceutical outsourcing is the key to resolving production bottlenecks and reducing costs whilst maintaining the highest quality standards. Increasing demands for GMP compliance, limited internal capacity and rising infrastructure and staffing costs are driving more and more manufacturers to outsource parts of their production to specialist service providers.
Pharmaceutical outsourcing refers to the outsourcing of production or filling tasks to external partners, known as contract manufacturing organisations (CMOs). These organisations handle the manufacturing and filling in accordance with the client’s precise specifications. The formulation, regulatory approval and marketing remain entirely the responsibility of the client company.
The model is well established within the industry. According to a market analysis by Mordor Intelligence, the European pharmaceutical contract manufacturing market is growing by around 5.7 per cent annually. This trend shows that outsourcing is no longer the exception, but an integral part of modern pharmaceutical strategy.
Benefits of pharmaceutical outsourcing for pharmaceutical companies
The benefits of pharmaceutical outsourcing can be divided into three distinct areas.
Cost savings and capital efficiency
Setting up your own sterile filling facility costs millions of euros. On top of this come ongoing costs for maintenance, cleanroom qualification, GMP audits and specialist staff. By outsourcing to a contract filler, you can avoid these investments entirely. Production costs become predictable and variable, as they scale directly with the order volume.
Flexibility and scalability
In-house production lines are designed for a specific capacity. Fluctuations in demand can quickly lead to overcapacity or underutilisation. A CMO, on the other hand, can respond flexibly: handling small batches for clinical trials as well as mass production for market launch.
Access to specialist technologies and expertise
Sterile filling, aseptic processes and ophthalmic preparations require highly specialised facilities and in-depth expertise. A CMO that specialises specifically in these product groups brings more experience to the table than an in-house department ever could. Find out which requirements need to be taken into account in our article on GMP-compliant sterile filling.
When exactly is pharmaceutical outsourcing worthwhile?
Not every business benefits equally from outsourcing. However, there are clear situations in which a contract bottler is the best solution.
Capacity constraints in our own production
Your own production facilities are running at full capacity, but new orders are coming in. If you don’t act now, you’ll lose customers or miss out on market opportunities. An external CMO can handle the extra volume at short notice and without the need for lengthy investment decisions.
Entry into new product lines or markets
A company wishes to launch sterile injection solutions or ophthalmic preparations onto the market for the first time. Setting up its own sterile production facility would take years and is hardly economically viable. A contract filling service enables the company to enter the market within a few months.
Lack of GMP infrastructure
GMP-compliant production requires suitable facilities, documented processes and regular audits. Many medium-sized pharmaceutical companies do not have the resources to set up and maintain this infrastructure in-house. A certified CMO solves this problem.
Clinical trials and small quantities
Phase I and Phase II trials often require small batches produced to the highest standards of precision. It is rarely cost-effective to produce these in-house. A contract filling service can produce precisely these quantities efficiently and in compliance with GMP standards.
Cost pressures and efficiency optimisation
When internal production costs become too high and competition drives prices down, outsourcing is an effective solution. This is particularly true when the CMO manufactures in a region with lower costs without compromising on quality standards. To find out more about how contract filling can be used strategically, read our article on contract filling as a strategic factor in pharmaceutical production.
Choosing the right outsourcing partner: What matters
Choosing the right CMO is crucial. The following criteria should be taken into account during the evaluation process.
GMP certification and quality standards
No product can be approved without GMP compliance. Check whether the contract filler holds up-to-date certifications or is currently undergoing a transparent certification process. The EU GMP standard is regarded as the international gold standard in this regard.
Specialisation in the relevant product group
A CMO that fills sterile injections, eye drops and liquid dosage forms brings a different set of skills to the table than a generalist. Make sure that the partner’s facilities and experience are a good fit for your product.
Available capacity and delivery capability
A packed order book at the CMO is of no use to you. Make sure you clarify right from the start whether the partner actually has the capacity to take on your project and whether they can scale up if demand increases.
Transparency and communication
A collaborative partnership requires open communication. Ask about project management processes, reporting standards and designated points of contact. As experts from the University of St. Gallen emphasise in an article for CHEManager, the requirements for professional CMO management vary greatly throughout the product lifecycle. A good CMO understands these dynamics and tailors their processes accordingly.
Location and logistics
The location of the contract manufacturer affects delivery times, transport costs and regulatory requirements. Nearshoring models, in which the CMO manufactures close to the EU border, combine cost benefits with short transport routes.
Frequently asked questions about pharmaceutical outsourcing
What is the difference between a CMO and a CDMO?
A CMO (Contract Manufacturing Organisation) handles production in accordance with the customer’s specifications. A CDMO (Contract Development and Manufacturing Organisation) also provides support with formulation development. Anyone who already has a finished product and is looking for a manufacturing partner will usually require a CMO.
As the client, will I lose control over my product?
No. As the client, you remain the legal and commercial owner of the formulation and the marketing authorisation. The CMO manufactures exclusively in accordance with your specifications. Quality agreements and audits ensure that you retain control over the entire production process.
How long does it take to commission a contract bottler?
That depends on the complexity of the product and the scope of the qualification requirements. Simpler projects can be up and running within a few weeks. For sterile products requiring extensive GMP documentation, a lead time of several months is realistic.
How much does pharmaceutical outsourcing cost?
Costs vary significantly depending on the product group, batch size and requirements. The key factor is a comparison with internal full costs, i.e. including capital expenditure, staff, training and day-to-day operations. In many cases, outsourcing is more cost-effective despite the mark-up.
Is outsourcing also suitable for small pharmaceutical companies?
Yes, often even more so. Small and medium-sized manufacturers benefit disproportionately because they rarely have the necessary resources to set up their own GMP-compliant facility. A contract bottler gives them access to infrastructure that would otherwise be unaffordable.
Fazit
Pharmaceutical outsourcing is not a stopgap measure, but a strategic decision with clear benefits. For those looking to avoid capacity bottlenecks, tap into new markets or reduce production costs, the right contract filling partner is a reliable ally.
The key factor here is the choice: the CMO must be a good fit for the product group, meet GMP standards and have genuine capacity. As a specialist CMO, Lubecafill focuses on sterile filling, injections, ophthalmic products and liquid dosage forms. With spare capacity, state-of-the-art facilities and a strategically located site near the EU border, we offer European pharmaceutical companies a reliable and scalable production solution.
Do you have any questions about your project? Get in touch now to secure production capacity.
